Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 2,500 hematologic oncology specialists to participate in the upcoming Tenth Annual Meeting of the Society (SOHO 2022). Click for more information and registration.

Register now
  • 6,157 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of nearly 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News

Brexucabtagene Autoleucel Receives Positive Opinion From EMA for R/R ALL

The EMA opinion is based on results from the phase I/II ZUMA-3 study of adults with R/R ALL

Sorafenib and Plerixafor Plus G-CSF Mobilizes Leukemia Cells, Leads to ‘Encouraging Rates of Respons

The chemotherapy-free treatment mobilized leukemia cells to peripheral circulation and led to “encouraging rates of response” in patients with R/R FLT3/ITD-mutated AML.

Study Shows Benefits of CAR T-Cell Therapy for Refractory Diffuse LBCL

A study in Spain showed that CAR-T therapy is superior to the previous standard of care for patients with refractory DLBCL.

Teclistamab Receives Positive Opinion From EMA for Adults with R/R Myeloma

The EMA’s recommendation is based on results from the phase I/II MajesTEC-1 study evaluating the safety and efficacy of teclistamab in adults with R/R MM.

EC Grants Full Marketing Authorization to Selinexor for Relapsed Myeloma

With this approval for the extension of the selinexor indication in the EU, the conditional marketing authorization is now converted to a full approval.

FDA Grants Fast Track, Rare Pediatric Disease Designations to WU-CART-007

The FDA has granted Fast Track Designation and Rare Pediatric Disease Designation for WU-CART-007 for the treatment of R/R T-ALL and ALL.

Liso-Cel Outperforms Standard of Care as Second-Line Treatment for R/R LBCL

The phase III TRANSFORM trial demonstrated the superiority of liso-cel as a second-line treatment for early R/R LBCL.

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top